Xenetic Biosciences, Inc. (XBIO)


-0.07 (-1.23%)
Symbol XBIO
Price $5.6494
Beta 2.875
Volume Avg. 0.02M
Market Cap 8.658M
Shares () -
52 Week Range 2.4-7.5
1y Target Est -
DCF Unlevered XBIO DCF ->
DCF Levered XBIO LDCF ->
ROE -30.18% Strong Sell
ROA -31.31% Strong Sell
Operating Margin -
Debt / Equity -
P/E -1.97 Sell
P/B 0.73 Buy


Consensus EPS

Upgrades & Downgrades

Latest XBIO news

Mr. Jeffrey F. Eisenberg Esq.
NASDAQ Capital Market

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.